Targeted protein degradation using proteolysis-targeting chimeras (PROTACs) has
emerged as an effective strategy for drug discovery, given their unique advantages over …

The field of targeted protein degradation (TPD) is a rapidly developing therapeutic modality
with the promise to tame disease-relevant proteins in ways that are difficult or impossible to …

The majority of eukaryotic messenger RNA precursors (pre-mRNAs) undergo cleavage and
polyadenylation at their 3′ end. This canonical 3′-end processing depends on sequence …

Small molecules that induce protein-protein interactions to exert proximity-driven
pharmacology such as targeted protein degradation are a powerful class of therapeutics 1 …

Targeted protein degradation (TPD) has emerged as a potentially transformational
therapeutic modality with considerable promise. Molecular glue degraders remodel the …

Molecular glues stabilize interactions between E3 ligases and novel substrates to promote
substrate degradation, thereby facilitating the inhibition of traditionally “undruggable” protein …

Degraders have illustrated that compound‐induced proximity to E3 ubiquitin ligases can
prompt the ubiquitination and degradation of disease‐relevant proteins. Hence, this …

RNA‐binding motif protein 39 (RBM39) is an RNA‐binding protein involved in transcriptional
co‐regulation and alternative RNA splicing. Recent studies have revealed that RBM39 is the …

Many essential biological processes are regulated through proximity, from membrane
receptor signaling to transcriptional activity. The ubiquitin-proteasome system controls …

Pre-mRNA splicing is the removal of introns and ligation of exons to form mature mRNAs,
and it provides a critical mechanism by which eukaryotic cells can regulate their gene …